Departments of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO 80045-0508, USA.
J Neurooncol. 2013 Aug;114(1):111-6. doi: 10.1007/s11060-013-1159-6. Epub 2013 Jun 2.
To report health-related quality of life (HRQOL) in glioblastoma (GBM) patients treated on a phase II trial of hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with temozolomide (TMZ). GBM patients received postoperative hypo-IMRT to 60 Gy in 10 fractions with TMZ. HRQOL was assessed using the EORTC quality of life questionnaire core-30 and the EORTC brain cancer module, performed at baseline, RT completion, 1 mo post-RT, and every 3 mos thereafter. Changes from baseline were calculated for each specific HRQOL scale. A ≥ 10 point change in any HRQOL scale from the mean baseline score was significant. 24 patients were treated. Compliance with HRQOL assessments at baseline, RT completion, and 1, 3, 6, 9, and 12 mos post-RT was 100, 96, 92, 79, 70, 68 and 53 %, respectively. Up to 12 mos post-RT, no significant changes were seen in global health status, physical functioning, role functioning, emotional functioning, fatigue, nausea, vision, headache or seizure. Significant improvement was seen in insomnia, future uncertainty, motor dysfunction and drowsiness. Significant worsening was observed in cognitive functioning, social functioning, appetite loss and communication deficit. 60 Gy hypo-IMRT in 6-Gy fractions with TMZ does not appear to negatively impact overall HRQOL.
报告接受分割强度调节放射治疗（hypo-IMRT）联合替莫唑胺（TMZ）治疗的胶质母细胞瘤（GBM）患者的健康相关生活质量（HRQOL）。GBM 患者在手术后接受 hypo-IMRT 治疗，剂量为 60 Gy，分割 10 次，同时服用 TMZ。使用 EORTC 生活质量问卷核心 30 量表和 EORTC 脑癌模块评估 HRQOL，在基线、放疗完成时、放疗后 1 个月和此后每 3 个月进行评估。对于每个特定的 HRQOL 量表，计算从基线的变化。任何 HRQOL 量表的变化与平均基线评分相比≥10 分是显著的。共治疗了 24 例患者。基线、放疗完成时以及放疗后 1、3、6、9 和 12 个月进行 HRQOL 评估的依从率分别为 100%、96%、92%、79%、70%、68%和 53%。在放疗后 12 个月内，全球健康状况、身体功能、角色功能、情感功能、疲劳、恶心、视力、头痛或癫痫无明显变化。失眠、未来不确定性、运动功能障碍和嗜睡显著改善。认知功能、社会功能、食欲减退和沟通障碍显著恶化。6 Gy 分割 hypo-IMRT 联合 TMZ 治疗 60 Gy 不会对整体 HRQOL 产生负面影响。
